Latest Conference Articles

Acknowledging and addressing maladaptive coping mechanisms may help reduce moral distress and burnout among oncology nurses.

Stephanie Jackson, DNP, MSN, RN, AOCNS, BMTCN, highlights how her unit leveraged an educational video to improve compliance with double verification for high-alert medications.

Eric Zack, DNP, RN, ACNP-BC, AOCN, BMTCN, describes disseminated intravascular coagulation and best nursing strategies to mitigate the severity of this condition.

Elizabeth R. Cullen, MSN, ARNP, highlights the efficacy of avasopasem manganese in mitigating severe oral mucositis in patients with locally advanced head and neck cancer.

Managing ocular-related adverse effects with mirvetuximab soravtansine is key to helping patients with ovarian cancer stay on treatment.

An analysis of the cilta-cel safety profile yielded promising results, according to nurse investigators.

Victoria R. Crowder, BSN, RN, and co-investigators, highlight existing gaps in the understanding of malnutrition risks facing patients with acute myeloid leukemia and myelodysplastic syndromes.

Donna Catamero, ANP-BC, OCN, CCRC, outlines best management strategies for treating patients receiving teclistamab who experience cytokine release syndrome.

Monitoring patients for cytokine release syndrome is a key aspect of caring for patients receiving teclistamab.

Specialists highlight the best practices and latest treatment regimens for patients presenting with myelofibrosis, polycythemia vera, and essential thrombocythemia.

Combined adjuvant treatment with mRNA-4157 in combination with pembrolizumab improved recurrence rates in patients with resected high-risk melanoma.

Patients who received pembrolizumab plus cisplatin and gemcitabine achieved a median overall survival of 12.7 months, compared with 10.9 months with cisplatin and gemcitabine alone.

A genome-wide methylome enrichment platform may help identify multiple early-stage cancers.

The pathologic complete response rate with durvalumab was 17.2% vs 4.3% with placebo, reflecting an absolute difference of 12.9%.

Findings from the TAPESTRY trial showed that approximately 40% of patients with genetic conditions may be missed by current NCCN guidelines.

Combined adjuvant treatment with atezolizumab and bevacizumab was determined to deliver a statistically significant recurrence-free survival benefit to patients with resected hepatocellular carcinoma.

Meghan K. Berkenstock, MD, discusses the growing need for strong collaboration between ophthalmologists and gynecologic oncology care teams.

Pembrolizumab inspired a 70% risk reduction in women with mismatch repair–deficient advanced endometrial cancer and a 46% risk reduction in patients with mismatch repair–proficient disease.

Mary Katherine Montes de Oca, MD, discusses the potential benefit of cryocompression therapy in preventing peripheral neuropathy in patients with gynecologic cancers who are receiving chemotherapy.

Lindsay Diamond, MSN, AGNP-C, AOCNP, discusses findings from CheckMate 274 and other data presented during the 2023 ASCO Genitourinary Cancers Symposium.

Patients with ovarian cancer who received hyperthermic intraperitoneal chemotherapy with cytoreductive surgery did not experience worse health-related quality of life, according to investigators.

Arash Rezazadeh Kalebasty, MD, discusses the rates of dose reduction and treatment discontinuation for patients with hormone-sensitive prostate cancer receiving combination therapy with darolutamide.

In the all-comer population, the overall response rate was 33.8%, including a complete response rate of 7.5% and a partial response rate of 26.3%.

Research presented at the 2023 Society of Gynecologic Oncology Annual Meeting On Women’s Health suggests that the Carolina frailty index score may be useful for women with ovarian cancer.

The gynecological cancer lymphedema questionnaire and the lower extremity lymphedema screening questionnaire showed a demonstrable correlation in total scores, according to an analysis of women with advanced endometrial cancer.

Terri Pollack, DNP, APRN, FNP-C, PMHNP-BC, discusses key data that may affect clinical practice for nurses from the 2023 GI Cancers Symposium.

In this episode of "The Vitals," Terri Pollack, DNP, APRN, FNP-C, PMHNP-BC, underscores potentially practice-changing data which were presented during the 2023 GI Cancers Symposium.

Nivolumab/Cabozantinib continued to outperform sunitinib in an updated analysis of the phase 3 CheckMate 9ER trial.